AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30013815
Drug: Phentermine-Topiramate Extended
RxNorm normalized name: phentermine / topiramate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine-Topiramate Extended Release, dosage and duration not available
Trial: 30015290
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GM and PCR (BAL) with BDG (serum)
Trial: 30016392
Drug: Vistusertib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vistusertib (50 mg bd for 3/7 days) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in HGSOC
Trial: 30016392
Drug: Vistusertib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vistusertib (25 mg bd after dose reduction) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in sqNSCLC
Trial: 30016415
Drug: Low pulse
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pulse pressure amplification (L-PPA)
Trial: 30016415
Drug: Systolic BP
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic BP (SBP) <130 mm Hg (L-SBP)
Trial: 30016929
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH)
Trial: 30016929
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (LMWH and low-dose aspirin)
Trial: 30016989
Drug: Drug-eluting microsphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting microsphere chemoembolization
Trial: 30017884
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg once daily as first-line treatment
Trial: 30018134
Drug: Fixed-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose subcutaneous trastuzumab (H SC) 600 mg every 3 weeks for 18 cycles
Trial: 30018558
Drug: Transcranial Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available.
Trial: 30018558
Drug: Placebo (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Control group), details on dosage and duration not available.
Trial: 30018811
Drug: TrasGEX (12-720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrasGEX (12-720 mg, intravenously every 3 weeks)
Trial: 30021547
Drug: Health worker
RxNorm normalized name: Apis cerana worker secretion preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health worker questionnaire administered at introduction and 6 months later
Trial: 30021548
Drug: CGA scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGA scores during the course of therapy (CGA1-4)
Trial: 30026059
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 or 750 mg daily)
Trial: 30026110
Drug: Nilotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (200 mg/day)
Trial: 30026275
Drug: Liraglutide (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (GLP-1 agonist), dosage and duration not specified
Trial: 30026911
Drug: Multi-platform information
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-platform information and communication technology intervention for neonatal resuscitation training; details on dosage and duration not available.
Trial: 30026911
Drug: Standard training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard training for neonatal resuscitation; details on dosage and duration not available.
Trial: 30027104
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 3.5 mg/kg/IFN-β
Trial: 30027478
Drug: Azilsartan 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 5 mg (for patients <50 kg)
Trial: 30027478
Drug: Azilsartan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 10 mg (for patients ≥50 kg)
Trial: 30028985
Drug: NIR intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR intraoperative imaging using TumorGlow (high-dose indocyanine green and delayed imaging)
Trial: 30031556
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with intramuscular injection (olanzapine, droperidol, haloperidol, benzodiazepine, ketamine)
Trial: 30032103
Drug: Work-focused cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-focused cognitive-behavioural therapy and individual job support
Trial: 30032814
Drug: Avitinib (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitinib (150-300 mg) twice daily for cycles of 28 days
Trial: 30032887
Drug: Levobupivacaine 0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25%, 20 ml with epinephrine 5 μg/ml
Trial: 30038037
Drug: Empirical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antimicrobial therapy (EAT) including vancomycin and broad-spectrum beta-lactam
Trial: 30038037
Drug: Empirical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antimicrobial therapy (EAT)
Trial: 30038390
Drug: Combined-intensified-modulated-adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-intensified-modulated-adjuvant treatment including RT and hormone therapy (HT) after RP.
Trial: 30038794
Drug: Multi-modal frailty
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal frailty intervention (tailored exercise program, protein supplementation, vitamin D supplementation, medication review)
Trial: 30039554
Drug: Gilteritinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib (20 to 300 mg/d, once daily)
Trial: 30039634
Drug: Brexpiprazole 1
RxNorm normalized name: brexpiprazole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 1 to 3 mg/day adjunct to current ADT
Trial: 30040168
Drug: Prexasertib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib (80 mg/m)
Trial: 30041614
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by adjuvant chemotherapy (reference treatment)
Trial: 30041962
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy (NCRT)
Trial: 30043115
Drug: Florbetaben injection
RxNorm normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Florbetaben injection (222-318.2 MBq, mean 270.1 ± 33.3 MBq)
Trial: 30043210
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks with methotrexate
Trial: 30044478
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for stage I seminoma (65 patients, 42.2%)
Trial: 30044478
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for high-risk stage I non-seminoma (23 patients)
Trial: 30044478
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for stage II seminoma (14 patients, 53.8%)
Trial: 30044478
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for stage III seminoma (all patients)
Trial: 30044478
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for stage II and III non-seminoma (all patients)
Trial: 30044693
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment for IKZF1 deletion
Trial: 30045838
Drug: Vadastuximab talirine
RxNorm normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadastuximab talirine (10 μg/kg) administered intravenously on the last day of hypomethylating agent (HMA) infusion (azacitidine or decitabine) in 4-week cycles.
Trial: 30046307
Drug: Kisspeptin-10 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kisspeptin-10 administration
Trial: 30046708
Drug: Idarucizumab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (up to 5 g as two consecutive intravenous infusions over 5-10 minutes each)
Trial: 30046714
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin gel (1120 IU/100 g), administered 2-3 times daily for 16 days
Trial: 30051292
Drug: Patient management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient management and treatment improvements
Trial: 30051298
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of a water-based, peelable nail polish
Trial: 30051298
Drug: 5% amorolfine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% amorolfine nail lacquer (weekly application)
Trial: 30052269
Drug: Alectinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (300 mg single dose) in moderate hepatic impairment (n = 8)
Trial: 30052269
Drug: Alectinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (300 mg single dose) in severe hepatic impairment (n = 8)
Trial: 30053006
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg apatinib once a day (q.d.)
Trial: 30053006
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg apatinib once a day (q.d.)
Trial: 30053905
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg BID for 6 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Trial: 30053953
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity (number of steps per day)
Trial: 30054122
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8 mg/kg every 4 weeks for 3 months as an add-on to glucocorticoids (prednisone starting at 0.7 mg/kg/day)
Trial: 30054977
Drug: Continued Appropriate
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued Appropriate Medical Therapy (CAMT)
Trial: 30055091
Drug: Antimalarial agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarial agents
Trial: 30055573
Drug: Intranasal challenge
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal challenge with wild-type influenza A/H1N1pdm virus
Trial: 30055613
Drug: Steroids, immunosuppressants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids, immunosuppressants, N-Acetylcysteine
Trial: 30055633
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard pharmacological treatment)
Trial: 30055824
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of inhaled nemiralisib (100 μg)
Trial: 30055824
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of inhaled nemiralisib (200 μg)
Trial: 30055824
Drug: Repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose of inhaled nemiralisib (200 μg for 10 days)
Trial: 30055824
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of inhaled nemiralisib (200 μg) with charcoal block
Trial: 30055837
Drug: Genotyping for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotyping for JS and complete age-appropriate ophthalmic examinations
Trial: 30056385
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention physiotherapy (treatment within 2 weeks after randomisation)
Trial: 30056385
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (treatment 6 weeks postrandomisation)
Trial: 30057012
Drug: Conivaptan (vasopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan (vasopressin V1A/V2 receptor antagonist)
Trial: 30060061
Drug: LY3039478 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3039478 (oral dose: 2.5-100 mg, thrice weekly on a 28-day cycle)
Trial: 30060061
Drug: LY3039478 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3039478 (oral dose: 45-100 mg)
Trial: 30060083
Drug: Venetoclax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR) given for six cycles at standard doses
Trial: 30060083
Drug: Venetoclax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR)
Trial: 30060328
Drug: Hypothyroidism treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothyroidism treatment
Trial: 30060328
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hypothyroidism treatment)
Trial: 30061026
Drug: Vaccine Hesitancy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Hesitancy Scale (VHS) survey tool
Trial: 30061051
Drug: Pfs25H-EPA/Alhydrogel 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25H-EPA/Alhydrogel 16 μg (pilot cohort)
Trial: 30061051
Drug: Pfs25H-EPA/Alhydrogel 47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25H-EPA/Alhydrogel 47 μg (main cohort)
Trial: 30061051
Drug: Pfs25H-EPA/Alhydrogel (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25H-EPA/Alhydrogel (after fourth dose)
Trial: 30061051
Drug: Pfs25H-EPA/Alhydrogel (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25H-EPA/Alhydrogel (after third dose)
Trial: 30061429
Drug: On-site monthly
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site monthly screenings of cardiovascular risk factors
Trial: 30061431
Drug: Pyridostigmine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (2 mg/kg/day to 6 mg/kg/day in four daily doses)
Trial: 30062043
Drug: Personalized intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalized intervention including reminders (audio and/or visual) and text message or automated phone call if a dose of medication is not taken within a pre-specified time frame.
Trial: 30062746
Drug: Higher opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher opioid dose
Trial: 30063383
Drug: MRI-guided stereotactic
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided stereotactic body radiation therapy (SBRT) up to a dose of 24 Gy in three fractions in 1 week
Trial: 30064401
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (wP) 40 to 75 mg/m² in combination with oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Trial: 30064401
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Trial: 30064418
Drug: Depression screening
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression screening and treatment integrated into HIV care initiation
Trial: 30064457
Drug: Log-HOMA-IR (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Log-HOMA-IR (insulin resistance)
Trial: 30064466
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral intervention administered through a smartphone app (CBIA)
Trial: 30064466
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral intervention administered through a smartphone app plus telephone conference calls (CBIA + TCC)
Trial: 30065032
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion during a mixed-nutrient meal
Trial: 30065032
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion during a mixed-nutrient meal
Trial: 30065032
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no infusion) during a mixed-nutrient meal
Trial: 30065100
Drug: MEDI3726 (ADCT-401),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3726 (ADCT-401), an antibody-drug conjugate targeting PSMA, consisting of an engineered anti-PSMA antibody J591 conjugated to the pyrrolobenzodiazepine (PBD) dimer tesirine.
Trial: 30065943
Drug: Spa treatment
RxNorm normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa treatment (3 weeks, 15 days of treatment, 120 to 150 minutes a day)
Trial: 30067493
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia (GA) using single bolus propofol (mean dose 2.1 ± 0.3 mg/kg) and sevoflurane
Trial: 30067922
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion test (copeptin cutoff >4.9 pmol per liter)
Trial: 30067922
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion test
Trial: 30068301
Drug: Neuroprotective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroprotective treatment with hypothermia
Trial: 30068505
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus lenalidomide (20 mg)
Trial: 30070770
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FF and BAT
Trial: 30070770
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of FF and BAT
Trial: 30071865
Drug: ENMD-2076 250
RxNorm normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENMD-2076 250 mg orally once daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity.
Trial: 30073432
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day for at least 7 consecutive days)
Trial: 30073583
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg bid plus docetaxel 75 mg/m²
Trial: 30073642
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) administered intravenously every 3 weeks until progression or unacceptable toxicity.
Trial: 30074111
Drug: Beta-Blockers (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Blockers (BB)
Trial: 30074111
Drug: ACE Inhibitors/Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE Inhibitors/Angiotensin Receptor Blockers (ACEi/ARB)
Trial: 30074259
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg orally, once daily in continuous 28-day cycles from day -3, plus intravenous cytarabine 100 mg/m².
Trial: 30074259
Drug: Cytarabine/daunorubicin (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine/daunorubicin (as part of the combination therapy).
Trial: 30076280
Drug: MRD-directed IFN-α
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD-directed IFN-α treatment
Trial: 30077125
Drug: Atezolizumab 1-20
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks
Trial: 30079582
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) drug levels < 200 ng/ml or undetectable desethylchloroquine